


For chemotherapy-induced anemia

Announcing a new  
J code: J0880



Aranesp®: the next-generation  
molecule proven to  
**power up  
erythropoiesis**



Aranesp® is indicated for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies.

Aranesp® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic and other serious events; dose reductions are recommended if the hemoglobin increase exceeds 1.0 g/dL in any 2-week period. The most commonly reported side effects in Aranesp® trials were fatigue, edema, nausea, vomiting, diarrhea, fever, and dyspnea; no important differences were observed between Aranesp® and Epoetin alfa.

*Please refer to the accompanying brief summary of the Aranesp® prescribing information.*

Reference: 1. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). *Br J Cancer*. 2001;84[suppl 1]:3-10.

**An approximately 3-fold  
longer half-life than  
Epoetin alfa powers...**

- More red blood cell production over time\*
- Early and sustained erythropoietic effect†
- **Less-frequent dosing than Epoetin alfa for more treatment-free days**

\*The clinical benefit of the pharmacokinetic data has not been determined.

For more information about Aranesp®, please visit our Web site at [www.aranesp.com](http://www.aranesp.com).



**Aranesp®**  
(darbepoetin alfa)

Powering up erythropoiesis